A study recently published in JAMA sheds light on cancer risks associated with carrying germline CDH1 mutations, challenging previous, potentially inflated, lifetime cancer risk estimates.
The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
